Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
5.75
+0.49 (9.32%)
At close: Dec 20, 2024, 4:00 PM
5.90
+0.15 (2.61%)
After-hours: Dec 20, 2024, 7:59 PM EST
Personalis Revenue
Personalis had revenue of $25.71M in the quarter ending September 30, 2024, with 40.89% growth. This brings the company's revenue in the last twelve months to $87.49M, up 24.05% year-over-year. In the year 2023, Personalis had annual revenue of $73.48M with 12.97% growth.
Revenue (ttm)
$87.49M
Revenue Growth
+24.05%
P/S Ratio
3.51
Revenue / Employee
$388,840
Employees
225
Market Cap
406.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ZimVie | 451.29M |
Quanterix | 129.33M |
Y-mAbs Therapeutics | 84.55M |
REGENXBIO | 84.33M |
Delcath Systems | 22.64M |
Taysha Gene Therapies | 9.92M |
Prime Medicine | 800.00K |
PSNL News
- 2 days ago - Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Business Wire
- 5 days ago - Personalis and Tempus Expand Collaboration to Biopharma - Business Wire
- 4 weeks ago - Personalis to Participate at Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Personalis Reports Third Quarter 2024 Financial Results - Business Wire
- 6 weeks ago - Personalis to Present at the Stifel 2024 Healthcare Conference - Business Wire
- 2 months ago - Personalis to Announce Third Quarter 2024 Financial Results - Business Wire
- 3 months ago - ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test - Business Wire